drugset

drugset / Trial / NCT04500717

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

NCT04500717 ↗

Phase 3 Unknown 460 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Jiangsu Hansoh Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, randomized, controlled, phase III study.

Timeline

Start: 2020-10
Primary completion: 2022-10
Completion: 2023-10

Publications

Duan JC, Zhong J, Sun BY, Zhao WH, Wu L, Fei KL, Chu Q, Guo QS, Song QB, Yu Y, Zhu DX, Liu XY, Zhao J, Zhan ZX, Li S, Nie L, Lin J, Peng XD, Zhong DS, Zhou J, Li LH, Chen YF, Hu C, Mok T, Wang ZJ, Wang J. Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. CA Cancer J Clin. 2026 Mar-Apr;76(2):e70071. doi: 10.3322/caac.70071.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Almonertinib	Small molecule	110 mg	Oral
Subject	Carboplatin	Small molecule	—	—
Subject	Pemetrexed	Small molecule	500 mg/m2	—

Indications